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Background: Although prophylaxis is a standard of care for young children in developed countries, known to
reduce the severity of hemophilic arthropathy, older adults with existing arthropathy have not traditionally used
prophylaxis. Recent studies have shown that adults with hemophilia A are increasingly adopting prophylaxis but
the characteristics of this treatment in older adults are not well understood. This multicenter observational study
was conducted to describe how secondary/tertiary prophylaxis is being used in older adults (≥40 years of age) in
comparison to younger adults with severe hemophilia A.
Methods: Eligible adult (≥18 years of age) Canadian males with baseline FVIII:C ≤2% from the participating
centres were observed over a 2 year period.
Results: Of the 220 adult severe hemophilia patients enrolled, 70% (155/220) used prophylaxis during the
observational period. Only 27% (60/220) are older adults with very few >60 years of age. A lower proportion of
older adults use prophylaxis compared to younger adults (58% vs. 75%, p = 0.016), with most patients in both
groups using continuous prophylaxis (92 and 94% respectively). When considering all treatment modalities
together, younger subjects use more factor concentrate than older subjects (2437 u/kg/year vs. 1702 u/kg/year,
p = 0.027); however, older subjects on prophylaxis use 3447 u/kg/year and had an ABR of 12 while those on
demand use 560 u/kg/year and had an ABR of 13.
Conclusion: A significant number of older adults use secondary/tertiary continuous prophylaxis in Canada,
accounting for a significant fraction of factor concentrate utilization.
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Prophylaxis, “treatment by intravenous injection of fac-
tor concentrate in anticipation of and in order to pre-
vent bleeding”, is a contemporary standard of care for
children and adolescents with severe hemophilia A in
the developed world [1]. When initiated in the absence
of documented osteochondral joint disease, and before
the second clinically evident large joint bleed (primary
prophylaxis) [2], benefits include: a reduction in number
of spontaneous joint and muscle bleeds, prevention or* Correspondence: sjackson@providencehematology.com
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unless otherwise stated.slowing of hemophilia related joint disease, reduced
hospitalization rates and times, improved school per-
formance and increased quality of life. [3,4]. Early
prophylaxis has allowed boys with hemophilia in devel-
oped countries to live with substantially less hemophilic
arthropathy and disability than past generations.
In Canada, individuals with moderate or severe hemo-
philia A older than 40 years often live with significant joint
disease from recurrent joint bleeds because prophylaxis
was not available until they were already adults. For the
most part, prophylaxis in adults was adopted after 1987
when later generation virally inactivated plasma-derived,
followed by recombinant, factor concentrates were avail-
able assuring both safety from blood-borne infection and
supply.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have emerged that describe 2 forms of prophylaxis that
are distinct from primary prophylaxis. Secondary prophy-
laxis (previously designated early secondary prophylaxis) is
the regular continuous treatment started after 2 or more
joint bleeds (but before the onset of joint disease detect-
able by physical examination or imaging studies) and ter-
tiary prophylaxis (previously designated late secondary
prophylaxis) is started after the onset of joint disease [2].
Recent evidence has suggested that, in spite of existing
joint arthropathy, tertiary prophylaxis offers benefit to
adults including decreased annualized bleeding rate (ABR),
less missed days of school/work and improved quality of
life [5-7]. A Canadian survey conducted in 2006 estimated
that 55% of adults with severe hemophilia A ≥ 18 years of
age, including 40% of those >50 years of age, were on
prophylaxis. On this background, we hypothesized that
prophylaxis in both age groups is increasing in Canada [8].
However, inherent differences in the older (≥40 years of
age) group who were not exposed to primary prophylaxis
in childhood resulting in a great burden of joint arthropa-
thy and co-infections, may alter how prophylaxis is used
when compared to the younger age group. Therefore, a
study was conducted to describe how secondary/tertiary
prophylaxis is being used in older adults (≥40 years of age)
in comparison to younger adults with severe hemophilia
A. Characterizing this older age group is important be-
cause their number will steadily increase until those ex-
posed to primary prophylaxis for most of childhood reach
this phase of life.
Methods
Canadian adult males, ≥18 years of age with severe hemo-
philia A (FVIII:C ≤2%), from 7 centres were included after
institutional review board approval from the following eth-
ics boards: University of British Columbia/Providence
Health Care Research Institute, University of Calgary, Uni-
versity of Saskatchewan, University of Western Ontario,
McMaster University, University of Toronto and Univer-
sity of Montreal. Inclusion criteria was intended to allow
those patients with both <1% and 1-2% FVIII who use
prophylaxis to be characterized because of the pheno-
typic overlap between moderately severe and severe
hemophilia A. Data was extracted retrospectively from
the medical chart and/or electronic medical record and
the local Canadian Hemophilia Assessment and Resource
Management System (CHARMS, http://ahcdc.ca/index.
php/charms) [9], with a standardized case report form at
each site. CHARMS was the primary source for factor
utilization data across centres and all utilization data was
extracted locally. Some centres use the system as a local
electronic medical record. The observation period was
from July 1, 2009 to June 30, 2011 (2 years). The local
medical chart and/or electronic medical record wasconsidered the primary source of information related to
the use of prophylaxis.
Prophylaxis was defined as the use of infused factor con-
centrate to prevent anticipated bleeding. Duration of ex-
posure was defined as either continuous with ≥ 45 weeks
of receiving prophylaxis, with the intent of treating
52 weeks per year, or intermittent (periodic) where the
treatment period did not exceed 45 weeks in a year, as per
the World Federation of Hemophilia definitions [2]. Inter-
mittent prophylaxis was further defined as short term (4–
11 weeks/year), where the intent is usually to temporarily
interrupt the bleeding cycle, or intermediate (12–44
weeks/year). Information was also gathered on whether
the prophylaxis regimen was stable or variable (including
with changes in dose or frequency, stopping or starting)
during the observation period.
Baseline data including type of hemophilia, baseline
factor VIII level, inhibitor history, number of joints af-
fected, prior experience with prophylaxis, co-infections,
and yearly factor concentrate utilization was gathered
from the clinic chart prior to July 1, 2009. All available
data related to prior prophylaxis exposures before 2009
was also collected. Bleed rate data was extracted from
patient-submitted paper or electronic bleed logs and fac-
tor VIII utilization extracted from the CHARMS data-
base, including factor utilization for 5 years prior to July
1, 2009 (‘pre-observation period’).
Subjects were excluded if less than 6 months of data
was available in the pre-observation period and/or if less
than 6 months of data was available during the 2 year
observation period. Data collected during the observa-
tion period included type of treatment (on-demand or
prophylaxis), duration of exposure to prophylaxis, dose and
frequency used, stability of dosage regimen, reasons for
starting, stopping or changing doses (when available), num-
ber of bleeds and yearly factor concentrate consumption.
Comparison of baseline demographic characteristics
between age groups and between baseline FVIII groups
was performed using Wilcoxon rank-sum test, chi-
squared test or Fisher’s Exact test as appropriate. The
univariate relationship between the outcome of prophy-
laxis exposure and clinical variables potentially associ-
ated with prophylaxis exposure in older subjects and
younger subjects were examined using Fisher’s exact test
or Chi square test or Wilcoxon rank-sum test as appro-
priate. Using multivariate logistic regression analysis, we
identify patient or hemophilia-related factors associated
with using prophylaxis during the observation period in
all subjects and in each age group. A stepwise regression
technique based on goodness of fit (AIC) was employed
to determine the set of variables that are most predictive
on the outcome. Linear regression analysis was used to
examine the relationship of factor utilization during
study period with age and annualized bleeding rate.
Table 1 Population demographics by age group
18-39 years ≥40 years p value
Number, % 160 (73) 60 (27) -
Median age (IQR), yrs 26.8 (21.9;32.4) 48.3 (43.7;52.6) -
Baseline FVIII:C, no. (%)
<1% 119 (74) 46 (77) NS
1% 25 (16) 10 (17) NS
2% 16 (10) 4 (6) NS
Time records available
Median (IQR), yrs 11.2 (4;19) 18.7 (11.1;28.8) <0.001
Range, yrs 0.5-38 0.5-48
Inhibitor status no. (%)1
Historical* 23 (15) 15 (25) NS
Current 2 (1) 6 (10) 0.002
Joints affected,
median no. (%)
0-1 79 (49) 15 (25) <0.001
2-4 73 (46) 31 (52) <0.001
>4 8 (5) 14 (23) <0.001
Prior Joint procedures, no.
Median 0 (0;1) 1 (0;3) <0.001
Range 0-4 0-8
Co-infections, no. (%)
HIV 40 (25) 35 (58) <0.001
HCV Ab 89 (56) 48 (80) 0.001
HCV RNA+ 50 (31) 31 (52) 0.005
HIV + HCV Ab 36 (23) 29 (48) <0.001
HIV + HCV RNA+ 27 (17) 22 (37) 0.002
HBSAg + 11 (7) 4 (7) NS
Median weight (IQR), kg 79.5 (69.5;88.5) 71.5 (63.5;79) 0.002
1Data missing for 2 subjects. *Includes transient and current inhibitors.
Jackson et al. BMC Hematology  (2015) 15:4 Page 3 of 8Results
Baseline characteristics
220 subjects with baseline FVIII ≤ 2% were included
representing 84% of the eligible population in participat-
ing centres. Treatment centres ranged in size of the se-
vere hemophilia A population (9–74 patients) but there
was no correlation observed between center size and en-
rollment rate (Kendall’s correlation = 0.048, p = 1). The
study includes 32% (165/509) of the Canadian adult
hemophilia A population with baseline FVIII:C ≤1%
[10]. Subjects with 1-2% FVIII:C activity at baseline rep-
resented 25% of the population (n = 55). Median (IQR)
age was 30.6 years (23.7; 41.6) with an age span of 18–
74 years. Baseline comparison between younger subjects
(18–39 years of age) and older subjects (40+ years of
age), who would not have had exposure to prophylaxis
as children, are shown in Table 1. As anticipated, older
subjects had a higher total number of joints with
hemophilic arthropathy, a history of more joint proce-
dures (including arthroplasty, fusion and radiosynovect-
omy), and a higher frequency of viral co-infections with
the exception of hepatitis B. In addition to these differ-
ences, the rate of current inhibitors was higher in the
older subjects at 10% versus 1% in those younger than
40 years of age (p = 0.002). Finally, the median body
weight of younger subjects was 8 kg (17.6 pounds)
higher than older subjects (p < 0.05). Prior to the study
period, the percentage of lifetime on secondary/tertiary
prophylaxis was 4% and 20% for older and younger age
groups respectively. Therefore, both age groups most
likely had established joint disease prior to the historical
initiation of prophylaxis consistent with the definition of
tertiary prophylaxis.
Prophylaxis exposure during observation period
The primary outcome of this study revealed that 70% of
subjects were exposed to prophylaxis during the 2 year
observation period and that older individuals were less
likely to use prophylaxis than younger patients (58% vs.
75%, p = 0.016), as shown in Table 2. 82-90% of the
youngest adults (18–27 years) were exposed to prophy-
laxis with a gradual decrease in the rate with age until
an abrupt increase back up to 82% was observed in sub-
jects 48–52 years (Figure 1). This is partially accounted
for by 3 individuals from that age group starting prophy-
laxis during the study period who were not undergoing
orthopedic or other surgery when prophylaxis was
started. Continuous prophylaxis (≥45 weeks of receiving
prophylaxis, with the intent of treating 52 weeks per
year) was used in 94% of those using prophylaxis during
the observation period and did not differ between the
age groups. The prophylaxis rate for subjects with base-
line FVIII:C 1-2% was 62% compared to 73% for subjects
with FVIII:C <1%.Stable prophylaxis
60% of subjects maintained a stable prophylaxis regimen
(no changes in dose or frequency) over the observation
period (Table 2). For those subjects, a median dose of
2000 units (range 500–4000 units) corresponding to 25 u/
kg/dose (range 6–64 u/kg/dose) was used. Older adults
used higher median weight-based doses when compared
to younger adults (26.8 vs. 24.6 u/kg/dose, p < 0.05) but
there was no statistical difference in median factor con-
centrate utilization per year between older and younger
adults on a stable regimen. The frequencies used were 3x
weekly (40%), 2x weekly (20%), every other day (12%),
daily (9%), 1x weekly (6%) and other/unknown (13%).
Variable prophylaxis
In those with variable regimens during the observation
period, the numbers who changed or stopped prophy-
laxis remained consistent over the age spectrum. It was








Prophylaxis, No (%) 155 (70) 120 (75) 35 (58) 0.0202
Stable regimen 103 (66) 77 (64) 26 (74) NS
Variable regimen: 52 (34) 43 (36) 9 (26) NS
Started 11 (21) 8 (19) 3* (33) NS
Changed 41 (79) 34 (79) 7 (78) NS
Discontinued 11 (21) 7 (21) 2 (22) NS
Type of
prophylaxis1
Continuous 144 (94) 112 (94) 32 (92) NS
Intermittent: 10 (6) 7 (6) 3 (8) NS
Short-term 3 (2) 1 (1) 2 (6)
Intermediate 7 (5) 6 (5) 1 (3)
*All from the age 48–52 year age group.
1Data missing for 1 subject.
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sons for starting, stopping or changing due to small
numbers in each subgroup. In those who started prophy-
laxis during the observation period the most common
reason, cited in 67% of cases, was frequent bleeding and/
or increased activity. For those who discontinued prophy-
laxis, the most common reason was patient desire because
of time required/inconvenience (36%), difficulty with IV
access (10%), patient desire for other reasons (20%) and in
36% discontinuation was documented without a reason. In
those changing the prophylaxis regimen, the reasons in-
cluded the health care professional recommending change
(21%), anticipated or actual increase in physical activity
(20%), frequent bleeding episodes (12%) and patient re-
quest due to IV access or other reasons (12%). Changes
were made in the minority of patients due to target joint,
major bleeding episode, orthopedic procedure, startingFigure 1 Rate of prophylaxis exposure over the age spectrum.anticoagulation, clinical improvement or other. In those
subjects who changed prophylaxis regimen, the most
common initial regimen was a median dose of 1500 units
(21.4 u/kg) given every other day.
Factors influencing prophylaxis
In the multivariate regression model including all sub-
jects, younger age was associated with an increased
probability of using prophylaxis, with an odds ratio of
1.04 per year of age decrease (95% CI, 1.01 to 1.07; p =
0.020). This was also seen in the multivariate analysis of
the 18–39 year old age group with an OR of 1.25 (95%
CI, 1.10-1.41; p = 0.004), but not in the older age group,
which was consistent with data presented in Figure 1.
None of the other factors including baseline factor activ-
ity, number of joints affected, number of prior joint pro-
cedures, coinfections, history of inhibitor and pre-study
weight were significantly correlated with the odds of
using prophylaxis in the all subjects analysis and in the
18–39 age group analysis. However, pre-study yearly fac-
tor consumption (per 10,000 u increase) did correlate
with increased odds of using prophylaxis, with an OR of
1.11 for all subjects (95% CI, 1.06 to 1.15; p < 0.001) and
1.36 for the 18–39 age group (95% CI, 1.21 to 1.53; p <
0.001). In the older age group, only a history of inhibitor
(either current or history of transient inhibitor) was
identified to have a significant negative influence on the
use of prophylaxis with an OR of 0.23 (95% CI, 0.06 to
0.83; p = 0.025).
Prophylaxis rate by treatment centre
The rate of prophylaxis use during the study period
among the 7 centres ranged from 45-95% distributed as
follows: <50% on prophylaxis (1 centre), 50-70% (2 cen-
tres), 71-90% (3 centres) and >90% (1 centre). Size of
clinic and local study inclusion rate did not correlate
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0.143 and −0.238 respectively; p = 0.773 and 0.562).
Factor utilization
Factor utilization data was available for 94% (206/220) of
the cohort during the 2 year observation period and for
93% (205/220) for the pre-observation period (5 years
prior). Factor utilization comprised total usage including
that used for prophylaxis and/or bleeds. Pre-observation
factor utilization (median u/kg/year) was 2057 u/kg/year
(IQR 1239, 3338) and similar in the pre-observation
period among all ages (Table 3). However, during the ob-
servation period those ≥40 years of age appeared to use
less factor overall than younger subjects (1702 vs. 2437
u/kg/year, p = 0.027). When utilization data from sub-
jects with current inhibitor (n = 8) were excluded this
difference was no longer significant (1824 vs. 2437 u/kg/
year, p = 0.120). Relationship between factor consumption
(u/kg/year) and age is shown in Figure 2 with an observed
trend towards decreasing overall factor utilization with
age, particularly in the on-demand group. However, for
those on prophylaxis, a trend towards increasing factor
utilization with age was also observed but there were only
a small number of older subjects. In the ≥ 40 year age
group, the largest discrepancy between factor utilization
for on-demand treatment versus prophylaxis was observed
(560 vs. 3447 u/kg/yr, p < 0.001), and this difference
remained significant when subjects with current inhibitor
were excluded.
Annualized bleeding rate
Bleeding log data during the observation period was
available for 87% (191/220) of the cohort. The median
(IQR) overall ABR during the study period was 7 (3;18)
bleeds/year (Figure 3). Those using prophylaxis had a
lower ABR when compared to on-demand (5 vs. 13
bleeds/year, p = 0.001). Older subjects had a higher ABR
than younger subjects (13 vs. 5 bleeds/year, p = 0.028)
but did not exhibit a difference in ABR between prophy-
laxis and on-demand use (12 vs 13, p = 0.866), in con-
trast to the younger group (4 vs 12, p < 0.001). If ABR
data from subjects with current inhibitor were excluded,
prophylaxis and on-demand ABR’s in the older group
remained similar (12 vs 16, p = 0.558) and ABR was un-
changed in the younger group. When the relationshipTable 3 Median (IQR) factor utilization (u/kg/year) before and
All subjects (n = 206) 18-39 y
Before 2057 (1239;3338) 2035 (12
During 2341 (1336;3650) 2437 (16
Prophylaxis 2707 (2049;3989) 2625 (20
On-demand 1066 (446;1718) 1371 (54
(p value) (<0.001) (<0.001)between factor utilization and ABR was examined, a
positive correlation between ABR and factor utilization
was observed only in those using on-demand treatment
(Figure 4).
Discussion
We have observed that 58% of older adults with severe
hemophilia A, who would not have had exposure to
prophylaxis until adulthood, are using long-term prophy-
laxis in Canada. This is a higher rate than previously re-
ported in the 2007 Canadian prophylaxis survey [8], where
40% of adults > 50 years of age were using some form of
prophylaxis, and a subsequent 2010 US survey where
prophylaxis was used in 44% of adults 45–64 years of age
(n = 454) and 32% of adults ≥65 years of age (n = 68) [11].
The definition of prophylaxis used in both surveys was
similar to those used in this observational study. An in-
creased prophylaxis rate in the younger adults was also
observed here in comparison to other previously pub-
lished adult North American cohorts [12-14] which sug-
gests that the use of prophylaxis is increasing over time in
both younger and older adults.
An evolving preference for prophylaxis over on-demand
therapy by both patients and health care professionals may be
the reason for this observation in a country with unlimited ac-
cess to factor concentrates. In Canada, while prophylaxis in
children is widely accepted [8,13] there are no formal guide-
lines to promote prophylaxis use in adults. However the
United Kingdom Hemophilia Centre Doctors’ Organization
(UKHCDO) and Medical and Scientific Advisory Council




Prophylaxis), have both endorsed that prophylaxis be
considered (or continued) in adults [15,16]. It has been dem-
onstrated that bleeding frequency decreases significantly in
adults who adopt long-term secondary prophylaxis after on-
demand treatment, with reported bleed rates down to a me-
dian of 0–1 bleed per year, under study conditions [5,17,18]
although only one study included adults > 50 years of age
[18]. Increasing awareness of this, along with other factors
such as improved quality of life, may be influencing the older
adults to accept a relatively new habit of regularly self-
injecting factor concentrate.during observation period
ears (n = 151) ≥40 years (n = 55) p value
39;3343) 2143 (1200;3307) NS




Figure 2 Annual factor utilization by age based for subjects
exposed to prophylaxis and on-demand treatment.
Figure 3 Annualized bleeding rate by age.
Figure 4 Annual factor utilization by annualized bleeding rate
for subjects exposed to prophylaxis and on-demand.
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was surprising to observe the ABR for those using on-
demand was similar to those using prophylaxis (12 vs 13
bleeds/year respectively). Furthermore, older adults used
higher weight based prophylaxis doses than younger
adults (26.8 vs. 24.6 u/kg/dose) but experienced almost
3-fold more bleeds annually. This finding contradicts the
usual observation that adults with severe hemophilia
tend to bleed less frequently than children, presump-
tively on the basis of lower levels of physical activity. A
possible explanation, particularly plausible in the obser-
vational setting, is that those older patients on prophy-
laxis originally had a much higher bleeding rate, which
might have prompted their decision to start prophylaxis.
Unfortunately, we cannot prove or deny this hypothesis
because of the incompleteness of the bleeding logs be-
fore the study. Since the majority of older men with se-
vere hemophilia will have at least 1 joint affected with
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have concurrent age-related osteoarthritis, there is also
potential for intermittent or chronic pain to be misinter-
preted as bleeding. This has been suggested by a recent
study, using point of care ultrasound, where the patient
perceived etiology of acute musculoskeletal pain in adults
with hemophilia was correct in only 1/3 of cases [19].
A variety of patient and hemophilia specific variables
were considered as possible predictors of prophylaxis
use in both older and younger groups. As expected, at
least in the younger group, younger age was independ-
ently associated with prophylaxis exposure but not other
plausible factors such as baseline FVIII:C activity, num-
ber of joints affected with arthropathy, prior joint proce-
dures, weight or co-infections. Factors not reflected in
the medical record might also exert influence over who
uses prophylaxis in both age groups including patient
personality, attitudes, lifestyle and vocation, relationship
with treatment centre, and inclination to follow treatment
recommendations. Likewise, treatment centre nurses and
physicians make their own opinion about who may benefit
and this would influence treatment decisions, which is
reflected in the observed variation of prophylaxis exposure
between centres.
Factor concentrate supply in Canada is widely available
through the medical system and affordability of factor
concentrates is not an issue for patients. Yet, Canadian
treaters appear to be conscientious of cost and conserva-
tive with respect to dosing. Overall annual factor
utilization for prophylaxis was observed to be 2707 u/
kg/year in this cohort, significantly lower than in Sweden,
where FVIII utilization generally reported at ≥4000 u/kg/
year [20], but higher than that reported by the Dutch
groups (~2100-2500 u/kg/year) [21]. However, the dis-
crepancy in factor utilization for prophylaxis by age group
was quite surprising with the older subjects on prophylaxis
using quite high amounts of factor and still exhibiting an
unacceptably high ABR. A prospective study with adjudi-
cation of bleeding events is needed to follow up on this
observation. However, a prospectively measured ABR col-
lected under the rigor of a clinical study may not reflect
the reality of measuring outcomes in ‘real life’ using bleed
logs.
The major limitations of this study include the reliance
on the medical record to reflect prophylaxis exposure ra-
ther than using data derived from patient home infusion
records which could theoretically reflect actual exposure
and adherence to prophylaxis. We could not accurately
and confidently reconcile the annual bleed data into
joint and non-joint bleeds nor provide joint scores for
the population. These and other limitations of an observa-
tional study are acknowledged however several intriguing
questions about the older population and their use of
prophylaxis are raised. Why do older individuals useprophylaxis if the overall rate of bleeding is not different
(at a population level) from those using on-demand? Why
do older individuals bother with this time intensive ther-
apy and is the benefit of prophylaxis measurable in this
age group? Do adults ≥ 40 years of age really bleed more
than younger adults? Given the current hemophilia guide-
lines that advocate to ‘treat with factor first’ an acutely
painful and/or swollen joint, how do hemophilia treaters
help older patients to differentiate a joint bleed from other
causes of acute joint pain? Finally, is this costly treatment
sustainable for the long-term with a growing number of
aging patients with severe hemophilia? An understanding
of the unique characteristics of a small population of older
individuals sets the stage for future work to identify older
patients who stand to benefit from this intensive and ex-
pensive form of treatment.
Conclusions
In this observational study, a significant number of older
individuals (≥40 years of age) with severe hemophilia
were using longterm continuous prophylaxis in Canada.
Weight based factor dosing and annual factor utilization
for prophylaxis was higher in this older group than in
younger individuals who had lower observed annual
bleeding rates. Further study to explore the optimal use
of prophylaxis in older individuals is warranted.
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